Pharmacologic Study of Oseltamivir in Healthy Volunteers

Phase 1

Completed

• Conditions: Avian Influenza A Virus

• Registration Number: NCT00439530
• Lead Sponsor: Mahidol University

Brief Summary

"Pharmacologic Study of Oseltamivir in Healthy Volunteers" is a Phase I study in which 8 to 32 adult healthy Thai volunteers will be randomized to one of four drug doses and regimens within each of 4 visits. The study is being conducted at the Bangkok Hospital of Tropical Diseases Research Unit, Faculty of Tropical Medicine, and commenced enrolling healthy volunteers on 23 November 2006. The duration of the study is expected to be approximately four months. The goals of this study are to assess the use of loading dose oseltamivir and the concomitant use of probenecid and to characterize the pharmacokinetic properties of oseltamivir in Thai subjects.

Detailed Description

Not available

Study Timeline

• Status Verified: 2006-11
• Study Start: 2006-11
• Study First Submitted: 2007-02-21
• Study First Submitted QC: 2007-02-21
• Study First Posted: 2007-02-23
• Primary Completion: 2007-04
• Study Completion: 2007-04
• Last Update Submitted: 2009-07-24
• Last Update Posted: 2009-07-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 21

Inclusion Criteria

• healthy with no underlying chronic disease
• normal baseline laboratory screening
• no regular prescribed medication used in the past 30 days and no over-the-counter medication in the past week
• agree to abstain from self-medication during the study
• negative urine pregnancy test for females and agreement that they will not try to become pregnant until 1 month after the study is completed
• only use non-hormonal methods of contraception for females
• non-smoker for the last 30 days and for duration of the study
• no consumption of alcohol for the last 30 days and for duration of the study
• no use of recreational drugs for the last 30 days and for duration of the study

Exclusion Criteria

• known hypersensitivity to oseltamivir and/or probenecid
• Hepatitis B virus surface antigen positive
• presence of intercurrent illness or any condition which in the judgement of the investigator would place the subject at undue risk or interfere with the results of the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Primary Outcome Measures

Name	Time	Method
AUC 0-12 hrs.	12 hour

Secondary Outcome Measures

Name	Time	Method
AUC 12-24 hrs.	24 hrs
C max	24 hrs
t max	24 hrs
t 1/2	24 hrs

Trial Locations

Locations (1)

Bangkok Hospital for Tropical Diseases Research Unit, Faculty of Tropical Medicine, Mahidol University; 🇹🇭 Bangkok, Thailand